Patient access to treatment remains poor. For the second year in a row, patients with chronic conditions rated health plan ...

The CDMO’s new services at its Hopewell, NJ facility delivers scalable, phase-appropriate production, in-house quality ...

In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.